Lisa Bodell: Change Is a Choice
In this article, Lisa Bodell challenges the way we typically think about change. Rather than viewing it as a dramatic, all-or-nothing leap, she reframes change…
Thought Leader: Lisa Bodell
Can an inflation cap on drugs be inflationary?
By Scott Gottlieb (original source AEI)
Members of the Senate Finance Committee have fashioned a well-meaning effort to modernize the Medicare drug benefit. Among its key features, the bill would help protect seniors from high out-of-pocket costs by limiting beneficiary cost sharing to $3,100 annually. It then seeks to offset some of these new subsidies by capping the increases that drug makers can take on the list price of their medicines.
In this way, the bill reflects a wider policy struggle underway in our debate over drug pricing. On the one hand, drug makers want to broaden coverage for medicines in programs like Medicare and Obamacare as a way to better insulate consumers from drug costs. On the other hand, policy makers don’t want to expand government funding for drugs without imposing more control over how these products are priced.
Click to read more
Relevant and recent posts
Erika Ayers Badan: 2025 In Review
I got a text the other night from my friend Erin letting me know that the year of the horse is in fact coming but…
Thought Leader: Erika Ayers Badan
Dr. Sanjay Gupta: Why You’re Breathing Wrong
Chronic disease, anxiety, ADHD, and even the shape of a person’s face could be consequences of dysfunctional breathing. And most of us, it turns out, are doing it wrong – but it’s never too late…
Thought Leader: Sanjay Gupta
More with this speaker
Dr. Scott Gottlieb on Finding Cures for Rare Diseases
Thought Leader: Scott Gottlieb
Dr. Scott Gottlieb: What’s Next for Childhood Vaccines
Thought Leader: Scott Gottlieb
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb